{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-030546","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2024-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.900017+00:00","generated_at":"2026-06-01T00:03:28.428425+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ovid/Graviton announce positive Phase 1 data for OV888/GV101 CCM therapy; Phase 2 expected H2 2024","bullets":["Phase 1 met primary safety/tolerability objectives: no serious adverse events at any dose.","Headache was most common AE (23%); all mild and resolved within 24 hours.","Target PK achieved: half-life ~12 hours supports once-daily dosing.","Dose-dependent decrease in proinflammatory cytokines IL-17 and IL-21 confirms ROCK2 target engagement.","Phase 2 proof-of-concept study in cerebral cavernous malformations planned for second half 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-030546","json":"https://secwatch.observer/filing/0001628280-24-030546.json","markdown":"https://secwatch.observer/filing/0001628280-24-030546.md","text":"https://secwatch.observer/filing/0001628280-24-030546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828024030546/0001628280-24-030546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828024030546/ovid-20240701.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:03:28.428425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}